ABC101-1, a novel microtubule inhibitor antibody-drug conjugate targeting HER2, has potent anti-tumor activity in a breast cancer model

被引：0
|
作者：
Kim, Seo Woo
Yu, Hana
Lee, Geon Ho
Lim, Tae Gyu
Jeong, Minji
Hwang, Hyeonjoo
Moon, Jee Eun
Lee, Yong Beom
Jin, Sung-Ha
Jeong, Jin Hyun
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 03期
关键词：
D O I：
10.1158/1538-7445.ADVBC23-B030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B030
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Evaluation of a Novel and Highly Efficacious Anti-HER2 Antibody-Drug Conjugate for HER2-Positive Breast Cancer Treatment
    Vuist, I.
    Oswald, E.
    Koehler, C.
    Sauter, P.
    Eades-Perner, A. M.
    Williams, C.
    Schueler, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S74 - S74
  • [22] MRG006A, a novel glypican-3-targeting antibody-drug conjugate, demonstrated potent anti-tumor activity and good safety profile in preclinical studies
    Wang, Yanchun
    Li, Hongfeng
    Shen, Hao
    Liu, Wenchao
    Liu, Shoujia
    Yin, Kequan
    Xu, Haili
    Cui, Xueyuan
    Li, Wei
    Liu, Wei
    Wu, Xiangyu
    Yang, Liu
    Ma, Tian
    Zhao, Zhongrun
    Wang, Jun
    Cui, Feifei
    Fang, Lei
    Qin, Minmin
    Hu, Chaohong
    CANCER RESEARCH, 2024, 84 (06)
  • [23] Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer
    Lei, Huizi
    Ling, Yun
    Yuan, Pei
    Yan, Xieqiao
    Wang, Lin
    Shi, Yanxia
    Yao, Xin
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    He, Zhisong
    Yu, Guohua
    Han, Weiqing
    Hu, Changlu
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Fang, Jianmin
    Guo, Jun
    Sheng, Xinan
    Zhou, Aiping
    Ying, Jianming
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 121 - 128
  • [24] Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells
    Kim, Hee-Jun
    Min, Ahrum
    Im, Seock-Ah
    Jang, Hyemin
    Lee, Kyung Hun
    Lau, Alan
    Lee, Miso
    Kim, Seongyeong
    Yang, Yaewon
    Kim, Jungeun
    Kim, Tae Yong
    Oh, Do-Youn
    Brown, Jeffrey
    O'Connor, Mark J.
    Bang, Yung-Jue
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 109 - 119
  • [25] Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
    Guidi, Lorenzo
    Pellizzari, Gloria
    Tarantino, Paolo
    Valenza, Carmine
    Curigliano, Giuseppe
    CANCERS, 2023, 15 (04)
  • [26] ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer
    Barok, Mark
    Le Joncour, Vadim
    Martins, Ana
    Isola, Jorma
    Salmikangas, Marko
    Laakkonen, Pirjo
    Joensuu, Heikki
    CANCER LETTERS, 2020, 473 : 156 - 163
  • [27] Development of a novel antibody-drug conjugate targeting endosialin/TEM-1: potent antitumor activity in sarcoma
    Sala, Gianluca
    Iacobelli, Stefano
    Capone, Emily
    PIccolo, Enza
    Sauniere, Jean-Fred
    Douet, Vanessa Vannucci
    CANCER RESEARCH, 2017, 77
  • [28] XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab
    Duvall, Jeremy R.
    Bukhalid, Raghida A.
    Cetinbas, Naniye M.
    Catcott, Kalli C.
    Lancaster, Kelly
    Bentley, Keith W.
    Clark, Suzanna
    Clardy, Susan
    Collins, Scott D.
    Dirksen, Anouk
    Ditty, Elizabeth
    Du, Bingfan
    Kelleher, Eugene W.
    Monnell, Travis
    Protopopova, Marina
    Routhier, Caitlin
    Stevenson, Cheri
    Ter-Ovanesyan, Elena
    Thomas, Joshua D.
    Uttard, Alex
    Wang, Jason
    Wongthida, Phonphimon
    Xu, Ling
    Yau, Annika
    Zurita, Jeffrey
    Toader, Dorin
    Damelin, Marc
    Lowinger, Timothy B.
    CANCER RESEARCH, 2022, 82 (12)
  • [29] The preclinical pharmacology of PRO1102, a novel exatecan-based HER2-directed antibody-drug conjugate with robust anti-tumor activity
    Wang, Lei
    Liu, Haidong
    Shang, Xiao
    Han, Tae H.
    Zhao, Baiteng
    CANCER RESEARCH, 2022, 82 (12)
  • [30] A bispecific HER2 targeting FynomAb with superior anti-tumor activity and novel mode of action
    Schade, Babette
    Brack, Simon
    Attinger-Toller, Isabella
    Klupsch, Kristina
    Woods, Richard
    Hachemi, Helen
    von der Bey, Ulrike
    Kooenig-Friedrich, Susann
    Bertschinger, Julian
    Grabulovski, Dragan
    CANCER RESEARCH, 2014, 74 (19)
12345